The generation of an effective AIDS vaccine is complicated by our incomplete knowledge of the correlates of immune protection during HIV infection. As such, it has been difficult to compare the potential clinical efficacy of the vectors that are currently considered as candidate AIDS vaccines. Notwithstanding these conceptual limitations, a number of clinical and pre-clinical immunogenicity indicate that replication-defective adenovirus (Ad) vectors based on the human serotype 5 (AdHuS) can induce strong and persistent immune responses to HIV/SIV antigens. Unfortunately, pre-existing exposure and/or immunity to human Ads, and particularly to AdHuS, may hamper the efficacy of AdHu5-based AIDS vaccines. The overarching hypothesis of this proposal is that chimpanzee (chimp) Ad-based vectors represent promising candidate AIDS vaccines as they show a profile of immunogenicity that is as good, if not better, than that observed for AdHuS while presenting only minor problems in terms of pre-existing immunity. The use of AdC6 and AdC7 as vaccine vectors was pioneered in the laboratory of Dr. Ertl, P.I. of this IPCAVD application. In Project #3 we propose to study in detail the impact of pre-existing Ad-specific T cells upon chimp Ad vaccine induced immune responses. In the first Aim, we will determine the prevalence, magnitude, functionality, and phenotype of naturally occurring AdC6 and AdC7-specific T cells in humans from North America and Africa.
In Aim 2 we will determine whether pre-existing AdHuS-specific T cells affect the immunogenicity of AdC6 and AdC7 SIV vaccine vectors, and alter the protective capacity of vaccine-induced cells after SIV challenge in rhesus macaques. In the final Aim, we will examine these same issues in humans vaccinated with the AdC6 and AdC7 vectors in phase I safety trials and a phase IIA immunogenicity trial. The levels of pre-existing AdHuS, AdC6, and AdC7-specific T cells will be assessed prior to challenge, and their impact upon vaccine immunogenicity and quality will be determined. Ultimately, the proposed studies are aimed at defining the impact of pre-existing Ad-specific T cell responses upon the efficacy of chmp Ad-based AIDS vaccines in inducing host responses that can contain virus replication, prolong disease-free survival, and decrease secondary transmission. Definition of the characteristics of such effective immune responses will also advance our understanding of the correlates of immune protection to be pursued in future efforts of AIDS vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI074078-05
Application #
8322805
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
2014-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2011
Total Cost
$413,402
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Emmer, Kristel L; Wieczorek, Lindsay; Tuyishime, Steven et al. (2016) Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. AIDS 30:2405-2414
Small, Juliana C; Haut, Larissa H; Bian, Ang et al. (2014) The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses. J Leukoc Biol 96:821-31
Tuyishime, Steven; Haut, Larissa H; Zhu, Caihong et al. (2014) Enhancement of recombinant adenovirus vaccine-induced primary but not secondary systemic and mucosal immune responses by all-trans retinoic acid. Vaccine 32:3386-92
Cervasi, Barbara; Carnathan, Diane G; Sheehan, Katherine M et al. (2013) Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac. J Virol 87:9420-30
Lasaro, Marcio O; Sazanovich, Marina; Giles-Davis, Wynetta et al. (2011) Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther 19:1727-36
Small, Juliana C; Ertl, Hildegund C J (2011) Viruses - from pathogens to vaccine carriers. Curr Opin Virol 1:241-5
Haut, Larissa H; Lin, Shih W; Tatsis, Nia et al. (2010) Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. Eur J Immunol 40:3426-38
Hutnick, Natalie A; Carnathan, Diane; Demers, Korey et al. (2010) Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28:1932-41
Chen, H; Xiang, Z Q; Li, Y et al. (2010) Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 84:10522-32
Hutnick, Natalie A; Carnathan, Diane G; Dubey, Sheri A et al. (2010) Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality. PLoS One 5:e14385

Showing the most recent 10 out of 18 publications